Expression of the complement regulatory proteins CD21, CD55 and CD59 on Burkitt lymphoma lines: their role in sensitivity to human serum-mediated lysis
- PMID: 1378022
- DOI: 10.1002/eji.1830220729
Expression of the complement regulatory proteins CD21, CD55 and CD59 on Burkitt lymphoma lines: their role in sensitivity to human serum-mediated lysis
Abstract
On a panel of nine human B cell lines we showed that the expression of the complement regulatory factors complement receptor type 2 (CR2; CD21), decay-accelerating factor, (DAF; CD55) and homologous restriction factor (HRF20, CD59) is not correlated. All lines expressed DAF, six lines carried detectable amounts of CR2 and three carried HRF20. Upon incubation in human serum, under conditions which allowed the activation of complement through the alternative pathway, the CR2-carrying lines bound C3 fragments and two of them (Ramos and one of its two sublines) were damaged. These two lines had the lowest DAF expression, less than 50% of the cells reacted with the IA10 monoclonal antibody. By modulating the expression of the complement regulatory molecules, the lytic sensitivity of the B cell lines could be altered. Blockade of DAF on the HRF20-, CR2+ lines with the specific monoclonal antibodies increased their sensitivity to lysis by human serum. With the DAF- and HRF20+ cells significant lytic effect was obtained only when they were pretreated with both of the specific antibodies. Interferon-gamma or tumor necrosis factor-alpha treatment elevated the amount of CR2 on the low-CR2 expressor line (Ramos/HR1K) which thereafter bound higher amounts of C3 fragments and was lysed when incubated in human serum. This line had relatively low DAF level and lacked HRF20. The cytokine treatment did not alter the expression of these molecules. The CR2+ Ramos and the CR2- Rael cells were treated with 5-azacytidine which induced HRF20 and increased DAF expression. In parallel with this change Ramos cells became resistant to C-mediated lysis. The experiments with the panel of human B cell lines showed thus that cytolysis through activation of complement in homologous serum can be regulated at several steps by cell surface molecules. While expression of CR2 was required for C3 fixation, DAF and HRF20 inhibited lysis. By independent modulation of the quantities of these molecules, cells acquired or lost their sensitivity.
Similar articles
-
Alternative complement pathway-mediated myeloid cell cytotoxicity: repertoire of membrane factors participating in regulation of C3 deposition and cytolysis.Eur J Immunol. 1991 Aug;21(8):1787-92. doi: 10.1002/eji.1830210802. Eur J Immunol. 1991. PMID: 1714391
-
Two modes of homologous C3 deposition on Ramos Burkitt's lymphoma cell substrains co-expressing DAF (CD55), CD59, and CR2 (CD21), and on cells lacking them.Int Immunol. 1992 Dec;4(12):1361-71. doi: 10.1093/intimm/4.12.1361. Int Immunol. 1992. PMID: 1283697
-
Protection of rat endothelial cells from primate complement-mediated lysis by expression of human CD59 and/or decay-accelerating factor.Transplantation. 1994 Dec 15;58(11):1222-9. Transplantation. 1994. PMID: 7527603
-
Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors.Mol Immunol. 2003 Sep;40(2-4):109-23. doi: 10.1016/s0161-5890(03)00112-3. Mol Immunol. 2003. PMID: 12914817 Review.
-
The control of homologous lysis.Immunol Today. 1991 Sep;12(9):312-5. doi: 10.1016/0167-5699(91)90005-E. Immunol Today. 1991. PMID: 1721817 Review.
Cited by
-
Receptors and Host Factors for Enterovirus Infection: Implications for Cancer Therapy.Cancers (Basel). 2024 Sep 12;16(18):3139. doi: 10.3390/cancers16183139. Cancers (Basel). 2024. PMID: 39335111 Free PMC article. Review.
-
Complement-mediated killing of microtumors in vitro.Am J Pathol. 1998 Sep;153(3):845-55. doi: 10.1016/S0002-9440(10)65626-X. Am J Pathol. 1998. PMID: 9736033 Free PMC article.
-
Cell-surface bound complement regulatory activity is necessary for the in vivo survival of KDH-8 rat hepatoma.Immunology. 1994 Aug;82(4):522-8. Immunology. 1994. PMID: 7835914 Free PMC article.
-
Enhanced complement resistance in drug-selected P-glycoprotein expressing multi-drug-resistant ovarian carcinoma cells.Clin Exp Immunol. 2009 Feb;155(2):239-48. doi: 10.1111/j.1365-2249.2008.03817.x. Epub 2008 Nov 24. Clin Exp Immunol. 2009. PMID: 19040611 Free PMC article.
-
Integrative Analysis of Complement System to Prognosis and Immune Infiltrating in Colon Cancer and Gastric Cancer.Front Oncol. 2021 Feb 3;10:553297. doi: 10.3389/fonc.2020.553297. eCollection 2020. Front Oncol. 2021. PMID: 33614473 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous